Inventia Life Science, a world chief in superior cell fashions for biomedical analysis and drug discovery, at this time introduced a collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) utilizing Inventia’s RASTRUM™ 3D cell tradition platform. By this collaboration, novel bioprinting capabilities supplied by RASTRUM™ might be utilised to create 3D in vitro fashions for the preclinical screening of neurodegenerative illness therapeutic candidates.
Picture Credit score: Inventia Life Science
Inventia is dedicated to working with MSD to determine higher in vitro fashions for neurodegenerative illnesses. By working collectively, we goal to determine new approaches to drug discovery and create extra translatable fashions which bridge the hole between in vitro and in vivo preclinical research.”
Dr Julio Ribeiro, Founder and CEO, Inventia
The RASTRUM™ platform is designed to allow the technology of extremely reproducible cell fashions that intently mimic the human mind. The collaboration goals to speed up the drug discovery course of by evaluating therapeutic candidates on 3D in vitro fashions of varied neurological issues, together with Alzheimer’s illness and Parkinson’s illness.
“This collaboration with Inventia leverages MSD’s deep experience in neuroscience and drug discovery with Inventia’s novel 3D bioprinting platform to develop extra related and translational fashions of the mind with the goal of enhancing preclinical screening for neurodegenerative illness candidates,” mentioned Dr. Jill Richardson, Govt Director of Biology, MSD, London.
